In the present paper, we report the synthesis, radiolabeling and comprehensive pharmacological evaluation of a C-terminally truncated tachykinin derivative, 3 
Introduction
The history of mammalian tachykinin discovery begins in 1931, when von Euler and Gaddum isolat ed a peptide from a preparation of equine brain and intestine. They characterized this peptide and named it "substance P". Further studies revealed that sub stance P caused vasodilation and stimulation of gut motility in rabbits. It was another 40 years before the amino acid sequence of substance P was confirmed. At that time, it was recognized that the sequence of substance P is similar to those of the tachykinins eledoisin and physalaemin, which were isolated from invertebrates [28] . Other endogenous tachyki nins (neurokinins A and B and hemokinin1) have been discovered more recently in vertebrates [19] . Primary structure activity relationship (SAR) studies on invertebrate tachykinins led to the conclusion that Cterminal hexapeptide amide fragments are fully responsible for the tachykininlike properties [1] . Further SAR studies on mammalian tachykinins also confirmed that the active fragments of tachy kinins (pharmacophores) have a common Cterminal sequence of YPheXGlyLeuMetNH 2 , where Y is any nonlipophilic amino acid residue and X is a lipophil ic alkyl (Val, Ile) or aromatic (Tyr, Phe) residue [11] . Three tachykinin receptors, termed NK 1 , NK 2 and NK 3 , were identified in the late 1980s as Gproteincou pled receptors (GPCR). The Nterminal fragments, as well as the type of lipophilic amino acid residue in the Cterminal fragments, modulate NKreceptor selectivity. The Nterminal fragments of tachykinins play a particularly important role in modulating selec tivity. The nature of these fragments decreases or increases affinities to particular NK receptor types, resulting in highly selective endogenous ligands. The order of affinities for different tachykinin recep tors toward mammalian tachykinins is as follows: for NK 1 , SP>NKA>NKB; for NK 2 , NKA>NKB>SP; for NK 3 , NKB>NKA>SP. Recently, a new chimeric type of GPCR ligand has been proposed that hybridizes pharmaco phores from different receptor types into one mol ecule [10] . The Cterminal fragments of tachykinins, or their analogues, have been hybridized with opioid pharmacophores to develop a new type of analge sic [6, 7, 11, 15, 16] . In multitarget receptor ligands it is important to evaluate the role of each separated target component. Therefore, we decided to synthe size and evaluate the Cterminal fragment of tachy kinin to identify specific roles for tachykinin phar macophores. The first amino acid in the Cterminal hexapeptide fragment is glutamine, which can be transformed easily to pyroglutamine. Both the Nter minal hexapeptide and its pyroglutamine analogue have very limited solubility in aqueous media. This creates the requirement that special solvents (DMSO or DMF) or carriers (dextran, cyclodextrin, albumin, etc.) be used for biological studies on these peptides. We thus decided to synthesize Lys [SP 711 ] as a pro spective tachykinin pharmacophore standard. This compound was originally synthesized as an ana logue of the nonmammalian tachykinin eledoisin, long before the sequence of substance P had been established [12] . In comparison with the activity of substance P, Lys [SP 711 ] shows a 200% greater hypo tensive effect in dogs and 100% greater GPI contrac tion. These results suggest that the pharmacological properties of this compound are similar to those of substance P.
Material and methods Chemicals
Protected amino acids were purchased from Sigma Aldrich, Merck Chemicals and Bachem. Cou pling reagents were obtained from Sigma Aldrich. All reagents and solvents were of reagent grade and were used without further purification. The mobile phases for linear gradient elution in RPHPLC con tained 0.05% trifluoroacetic acid (TFA) in water or acetonitrile. The stationary phase was a Jupiter Pro teo C12 column. A Shimadzu LCMS liquid chromato graph with an attached ESI mass spectrometer was used to identify the peptides.
Selective In vitro pharmacological evaluation of the radiolabeled C-terminal substance P analogue Lys-Phe-Phe-Gly-Leu-Met-NH2: Does a specific binding site exist? The halogenated hexapeptide precursor was triti ated by the general method reported previously [31] . The halogenated precursor HLyspIPhepIPheGly LeuMetNH 2 (3.6 mg, 2.95 µmol) was dissolved in DMF (1 ml). To this solution was added PdO/BaSO 4 catalyst (10 mg) and triethylamine (TEA, 5 µl). The re action mixture was stirred for 1 h in the presence of 3 H 2 at room temperature. When the reaction was complete, the mixture was filtered through a What man GF/C glass fiber filter and washed several times with EtOH:H 2 O (1 : 1, v/v) to remove the catalyst and labile tritium. The total activity of the crude prod uct was determined in a toluenebased scintillation cocktail using a TRICARB 2100TR Liquid Scintillation Counter (CanberraPackard, PerkinElmer Life Scienc es, 549 Albany Street, Boston, MA 02118), and was found to be 110 mCi (4.1 GBq). The crude [ 3 H]KFF GLMNH 2 was then purified by RPHPLC, and its puri ty was determined to be greater than 95%. Specific radioactivity was found to be 24 Ci/mmol (0.89 TBq/ mmol). The radioligand was taken up in spectrosco pic grade ethanol containing 0.1 mM LMet and stor ed in liquid nitrogen.
Rat brain membrane preparation
Rats (male and female Wistar, 250300 g, 23 months old) were kept in groups of four under stan dard conditions with access to food and water ad libitum. The animals were handled according to the guidelines of the European Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII. tv. Section 32). Crude membranes of rat brains without cerebellums were prepared by a standard protocol as described earlier [2] . The brain homogenates were kept frozen in liquid nitrogen. On the day of the exper iment, rat brain homogenates were thawed, diluted with working buffer and centrifuged at 20,000 × g to remove sucrose. The pellet was homogenized with a Dounce homogenizer in an appropriate volume of binding buffer (50 mM TrisHCl, pH 7.4, 0.1% BSA, 3 mM MnCl 2 and protease inhibitor). Protein content was determined using the Bradford assay with BSA as the standard.
Radioligand binding assays
All binding experiments were carried out at 25°C in a final volume of 1 ml containing 0.30.5 mg/ml membrane in neurokinin buffer. This buffer consisted of 50 mM TrisHCl (pH 7.4), 0.1% BSA, 3 mM MnCl 2 and protease inhibitor. In the kinetic experiments, the time course of association was measured by incubating 2.0 nM [ 3 H]KFFGLMNH 2 with the protein for 60 minutes. In the dissociation experiments, the radioligand was preincubated with the membrane until equilibrium was reached (60 minutes). A solution of 10 µM unlabeled HKFF GLMNH 2 was then added to induce dissociation of the radioligand. This process was typically complete after 60 minutes. Saturation binding experiments to determine the equilibrium dissociation constant (K d ) and maximum number of binding sites (B max ) were performed with increasing concentrations (0.1 10 nM) of [ 3 H]KFFGLMNH 2 . Homologous and heter ologous competition binding experiments were car ried out by incubation of rat brain membranes with 3 nM [ 3 H]KFFGLMNH 2 in the presence of increasing concentrations (10 10 10 5 M) of unlabeled neuroki nin ligands. Nonspecific binding was determined with 10 µM HKFFGLMNH 2 and subtracted from the total binding to obtain specific binding. Incubations were terminated by the addition of icecold buffer (50 mM TrisHCl, pH: 7.4, 0.05% BSA). A Brandel Cell Harvester (Gaithersburg, MD, USA) was then used to filter cells rapidly with Whatman GF/B glass fiber filters presoaked in PEI. Filters were immersed directly in Optiphase Supermix scintillation cocktail (PerkinElmer) and assessed in a TRICARB 2100TR liquid scintillation counter. The results presented are mean values ± SEM of at least five independent experiments, each performed in duplicate. Kinetic data were calculated to obtain the rate constants for association (k a ) and dissociation (k d ). Nonlinear regression analysis of direct saturation isotherms was used to obtain values for the equilibrium dis sociation constant (K d ) and receptor density (B max ). Inhibitory constants (K i , nM) were calculated from competition binding experiments using nonlinear leastsquare curve fitting and the ChengPrusoff equation with GraphPad Prism software (version 4.0, San Diego, CA, USA) [5] . 
Ligand-stimulated [ 35 S]GTPγS functional assay

Results
The synthetic peptide was selected for tritium labeling (Table I) The association rate constant, k a , was determined from this value to be 0.0181 ± 0.0009 nM -1 min -1 (Table II) . Dissociation was measured by preincubat ing the radioligand with the receptor until equilibri um; subsequent addition of 10 µM un labeled ligand initiated dissociation (Fig. 1B) . The dissociation iso therm followed monophasic kinetics and provided a dissociation rate constant (k d ) of 0.1263 ± 0.0422 min -1 . The equilibrium dissociation constant (K d ), cal culated from these two rate constants, was found to be 6.9 ± 1.8 nM. The saturation isotherm showed that the specific binding of [ 3 H]KFFGLMNH 2 was In vitro pharmacological evaluation of the radiolabeled C-terminal substance P analogue Lys-Phe-Phe-Gly-Leu-Met-NH2: Does a specific binding site exist?
a highaffinity, saturable interaction (Fig. 2) . Fitting the direct saturation plot to a "onesite" binding model gave a K d of 7.1 ± 2.2 nM, which was in good agreement with that determined from the kinetic curves (Table II) . Receptor density (B max ) was calcu lated to be 257 ± 46 fmol × mg protein -1 , a value that is several orders of magnitude greater than those reported in the literature for substance P (SP) [20] . The sites on the receptor where the radioligand binds were characterized through displacement binding experiments using receptor selective com petitors of the radioligand in rat brain membrane homogenates (Fig. 3AC) . The inhibitory constants (K i ) determined through these experiments are sum marized in Table III . The majority of neurokinin recep tor specific ligands displaced the radioligand with micromolar inhibitory constants (K i -µM) reflecting the low affinity of the radioligand for these recep tors. This contrasts markedly with literature data reported for SP [17, 20] . The highest affinity was found for the nonpeptidic NK1 receptor antagonist Increasing concentrations of radioligand (0.1 10 nM) were incubated with rat brain mem brane as described in the Material and methods section. Values for the dissociation equilibrium constant (K d ) and receptor density (B max ) were determined directly from the saturation plot. The value of B max was then converted to fmol × mg protein -1 . Only specific binding is reported. of the radioligand (K i = 0.580 ± 0.103 µM). Other derivatives proved to be poor inhibitors of radioli gand binding, suggesting that truncation of neu rokinin Nterminal sequences is not favorable for selective receptorligand interactions. Interestingly, unusual behavior was observed for two receptor selective ligands and receptor types. Positive cooper ativity could be observed for a peptidic NK2 agonist, (Nle 10 )neurokinin A (410) (Fig. 3B) . Increasing the concentration of (Nle 10 )neurokinin A (410) to 10 -5 M while maintaining a constant radioligand concentra tion led to a massive accumulation of radioligand. This outcome manifests itself in an "inverse" behav ior. This feature suggests the likelihood of positive allosteric modulation, the existence of multiple bind ing sites or multiple conformational states of the receptor protein. Any of these could trigger concom itant binding of two different ligands, likely at two distinct binding sites. This is very interesting given that the analysis of kinetic data using the "two site" binding model for the radioligand failed to provide L703,606 oxalate, which inhibits radioligand binding with a K i value of 0.087 ± 0.016 µM. This K i is more potent than that observed for the unlabeled analogue
In vitro pharmacological evaluation of the radiolabeled C-terminal substance P analogue Lys-Phe-Phe-Gly-Leu-Met (Fig. 4, Table IV ). Both ligands showed potency toward activation of G proteins, with EC 50 values of 313 ± 36 nM (HKFFGLMNH 2 ) and 892 ± 65 nM (SP). The corresponding efficacies were found to be 142 ± 9% (HKFFGLMNH 2 ) and 120 ± 4% (SP). These results strongly suggest that the ligands are agonists of the NK receptors, indicating that targeted Nterminal truncation and modifica tion of SP do not profoundly influence its functional properties. The relatively low efficacy found for SP may be attributed to the presence of fewer NK1 binding sites in rat brain compared with the num ber of primary sites in the spinal cord. The function al data measured for the coapplication of receptor antagonists and HKFFGLMNH 2 confirmed that the hexapeptide binds to neurokinin receptors and acti vates Gprotein coupling that could be abrogated by the selective antagonists.
Discussion
Numerous structureactivity relationship stud ies have shown that the Cterminal component of neurokinin ligands (especially the Cterminal penta peptide PheXGlyLeuMetNH 2 motif, where X is a hydrophobic amino acid residue) is critical for spe cific binding of highaffinity agonists to receptors in the tachykinin family [4, 20, 22, 26, 27, 33] .
All Cterminal tachykinin fragments interact with similar binding sites of their receptors. For these fragments there exist some common structural requirements. For example, peptide mapping studies of the NK 1 receptor have established that the site of interactions of both SP and NKA is located within the same segment of the receptor [3, 33] . The Nterminal fragments of tachykinins play a role in modulating the selectivity of endogenous ligands by decreasing or increasing affinities to par ticular NK receptor types. In addition, Nterminal fragments can carry out their independent neuro modulatory functions in intact endogenous peptides or as metabolites [8] . Our strategy was to truncate and modify the structure of the Cterminal fragment of an NK receptor agonist to prepare a tractable radi oligand that could be used to investigate the tachy kinin system. Our results further confirmed the fact that subtle differences in structure and chain length can result in striking changes in the mode of ligand binding, and presumably have an effect on GPCR signaling. The first intriguing finding came from kinetic experiments, which revealed unusually high receptor density (B max ) and a relatively high value for K d compared with those reported for SP in rat brain [20] . Park et al. (1984) reported a single high affinity (K d = 0.3 nM) and low density (B max = 27.7 fmol mg protein -1 ) class of binding sites for SP in rat brain. Additionally, the relative potencies of various SP fragments for [ 3 H]SP binding sites were found to be roughly proportional to the length of the Cter minal fragments. We hypothesize from these data that the hexapeptide binds to multiple regions, con formational states or subtypes/splice variants of the receptor proteins. Some of these binding sites may not be identical to the "conventional" binding sites or conformational states for the endogenous neu rokinin ligands or receptors. [9, 13, 14] . However, these possibilities have yet to be explored.
The Nterminally truncated and modified hexa peptide retained its functional agonist activity and stimulated Gprotein coupling. Its overall behavior was similar to that observed for the parent peptide SP. The increased potency and efficacy of HKFF GLMNH 2 over those of SP also suggest a different mode of ligand binding. However, all of the NKre ceptor antagonists could inhibit ligand activity at relatively low concentrations. While it has yet to be investigated, it is possible that ligand binding may alter Gprotein signaling. It has also been demon strated that the endogenous or exogenous ligands for neurokinin receptors can induce conformational statedependent or ligand bindingdependent mod ulation of various signal transduction pathways. This can lead to such diverse responses as calcium release and cAMP production, or initiation of recep tor desensitization [18, 21, 23, 29] . In addition, deriv atives of SP modified at the Cterminus have been described that can behave as both agonists and antagonists of the NK1 receptor, depending on the second messenger pathway [18, 23] . Taking the liter ature data and our findings together, we speculate that our ligand interacts with binding sites specific to Cterminal tachykinin binding sites ("tachykinin In vitro pharmacological evaluation of the radiolabeled C-terminal substance P analogue Lys-Phe-Phe-Gly-Leu-Met-NH2: Does a specific binding site exist?
pocket"). These sites are structurally similar for all tachykinin receptors. The endogenous ligands of at least three receptors (NK 1 , NK 2 and NK 3 ) have Nter minal fragments that enhance affinity to one type of receptor while decreasing affinity for other types. Our results may also suggest the existence of other tachykinin binding sites that preferentially recognize the HKFFGLMNH 2 motif. However, this binding site (or sites) is characterized by broad recognition of all tachykinin ligands and attenuated recognition of the Nterminal fragments that usually increase ligand selectivity and affinity. Mysteriously, two previously observed specific binding sites are not present in stable equivalent amounts, suggesting the influence of other modu latory elements [25] . All interpretations of previous observations of various binding sites have been constructed with prediction of tachykinin recep tors' existence in monomeric form. However, in the light of our data, we hypothesize that dimers of NK receptors could be specific receptor(s) for Cterminal fragments, including HKFFGLMNH 2 . Previous dis cussions on other types of GPCR led to the sugges tion that dimerization of receptors may result in the formation of an additional allosteric binding site or sites [30] . It should also be considered that interac tion of receptor domains in the dimerization process may also destroy "allosteric pockets" as the result of structural reorganization required to form a dimeric macromolecule (Fig. 5 ). In such a case, Cterminal hexapeptide fragment analogues may have less specific interactions with all tachykinin receptors in both monomeric and dimeric forms. Fully elongated undecapeptide substance P interacts with both the "tachykinin pocket" and the "allosteric pocket" on the monomeric NK1 receptor (Fig. 5A) . Interactions with the dimeric form are limited to the "tachykinin pockets". The obtained results on pharmacological . Illustration of substance P interacting with monomeric and dimeric NK 1 receptor. In the monomer, the interaction of the Cterminal fragment of substance P with the "tachykinin pocket" is enhanced by allosteric interaction of the Nterminal fragment with the "allosteric pocket". Dimerization of receptors blocks the "allosteric pockets". "Tachykinin pockets" in the monomeric and dimeric forms are recognized equally well by KFFGLMNH 2 .
properties of HKFFGLMNH 2 were quite unexpected. This allowed us to construct the working hypothesis. However, for confirmation it is necessary to define a new avenue of investigation that will be explored in our further studies.
